|Day Low/High||35.19 / 37.55|
|52 Wk Low/High||14.70 / 50.11|
Cabiralizumab (FPA008) is in a Phase 2 clinical trial for rare neoplastic joint disease for which there are no currently approved treatments
Shares tanked Wednesday on little more than a two-sentence comment from the president-elect.
In recent trading, shares of Five Prime Therapeutics, Inc have crossed above the average analyst 12-month target price of $56.00, changing hands for $57.76/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Trade-Ideas LLC identified Five Prime Therapeutics (FPRX) as a new lifetime high candidate
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 523,826 share increase in total short interest for Five Prime Therapeutics, Inc , to 3,441,775, an increase of 17.95% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.